<p>Clene（納斯達克代碼：CLNN - 獲取免費報告）於週三發佈了季度財報。該公司報告的每股收益（EPS）為（$0.85），低於市場共識預期的（$0.60），差距為（$0.25），FiscalAI 報道。該季度的收入為$0.02 百萬。</p>
<h2>Clene 股價下跌 17.4%</h2>
<p>週四交易時段，CLNN 股票下跌$1.64，報$7.77。該公司交易了 95,600 股股票，較其平均交易量 88,419 股有所增加。Clene 的 52 周低點為$2.28，52 周高點為$13.50。該股票的 50 日移動平均為$8.10，200 日移動平均為$5.29。公司的市值為$78.24 百萬，市盈率為-2.07，貝塔值為 0.72。</p>
<h2>機構資金流入與流出</h2>
<p>一家機構投資者最近在 Clene 股票上建立了新頭寸。根據該公司在最近向證券交易委員會（SEC）提交的 13F 文件，Jane Street Group LLC 在第二季度收購了 Clene Inc.（納斯達克代碼：CLNN - 免費報告）的新股份。該機構投資者收購了 12,095 股公司股票，價值約$47,000。Jane Street Group LLC 在最近的報告期末持有 Clene 約 0.15% 的股份。機構投資者持有該公司 23.28% 的股份。</p>
<h2>分析師評級上調與下調</h2>
<p>幾位股票分析師對該股票發表了評論。華爾街 Zen 在 8 月 16 日的報告中將 Clene 的評級從 “持有” 下調至 “強烈賣出”。Canaccord Genuity Group 在 8 月 18 日的研究報告中將 Clene 的目標價從$83.00 下調至$48.00，並對該股票給予 “買入” 評級。D. Boral Capital 在 9 月 25 日的研究報告中重申了 “買入” 評級，並將 Clene 的目標價設定為$23.00。Weiss Ratings 在 10 月 14 日的研究報告中重申了對 Clene 的 “賣出（d-）” 評級。最後，Benchmark 在 9 月 10 日的研究報告中將 Clene 的目標價從$33.00 下調至$31.00，並對該股票給予 “買入” 評級。五位研究分析師對該股票給予 “買入” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，平均目標價為$32.60。</p>
<p><strong>查看我們最新的 Clene 股票報告</strong></p>
<h2>Clene 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Clene Inc 是一家臨牀階段的製藥公司，專注於新型清潔表面納米技術（CSN）治療藥物的發現、開發和商業化。其主要藥物候選者是 CNM-Au8，目前正在進行多項臨牀試驗，包括一項已完成的第二階段平台試驗，以評估 CNM-Au8 在肌萎縮側索硬化症（ALS）患者中的安全性和有效性；已完成的第二階段概念驗證臨牀試驗，針對早期症狀性 ALS 患者；已完成的兩項開放標籤研究者盲法第二階段臨牀試驗，研究大腦能量代謝物；已完成的第二階段臨牀試驗，治療慢性視神經病變中的視覺通路缺陷，以實現穩定復發型多發性硬化症的再髓鞘化；以及針對帕金森病患者的第二階段臨牀試驗。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票</li>
<li>選舉股票：選舉如何影響股市</li>
<li>AMD 到$300 看起來很容易——這是為什麼$500 可能是下一個</li>
<li>如何逐步購買便宜股票</li>
<li>超過$5B 的回購：DraftKings、AppLovin 和 Altria 在告訴你什麼</li>
<li>內部購買解釋：投資者需要知道什麼</li>
<li>4 只高收益房地產股票，適合投資者採取防禦性策略</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xOTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xOTg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Clene 嗎？</h2>
<p>在考慮 Clene 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Clene 並不在名單上。</p>
<p>雖然 Clene 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

CLNN

<p>Clene (NASDAQ:CLNN) 報告的季度每股收益 (EPS) 為 ($0.85)，低於市場共識預期 $0.25。該季度公司的收入為 0.02 百萬美元。在財報發佈後，Clene 的股價下跌 17.4%，至 $7.77。機構投資者持有該股票的 23.28%，最近有來自 Jane Street Group LLC 的活動。分析師的評級不一，整體評級為適度買入，目標價為 $32.60</p>

<p>Clene (NASDAQ:CLNN - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.25), FiscalAI reports. The business had revenue of $0.02 million for the quarter.</p>
<div class="lb-trans"><p>Clene（納斯達克代碼：CLNN - 獲取免費報告）於週三發佈了季度財報。該公司報告的每股收益（EPS）為（$0.85），低於市場共識預期的（$0.60），差距為（$0.25），FiscalAI 報道。該季度的收入為$0.02 百萬。</p>
</div><h2>Clene Trading Down 17.4%</h2>
<div class="lb-trans"><h2>Clene 股價下跌 17.4%</h2>
</div><p>Shares of CLNN stock traded down $1.64 during trading hours on Thursday, reaching $7.77. 95,600 shares of the company's stock were exchanged, compared to its average volume of 88,419. Clene has a fifty-two week low of $2.28 and a fifty-two week high of $13.50. The stock's 50 day moving average is $8.10 and its 200-day moving average is $5.29. The company has a market cap of $78.24 million, a price-to-earnings ratio of -2.07 and a beta of 0.72.</p>
<div class="lb-trans"><p>週四交易時段，CLNN 股票下跌$1.64，報$7.77。該公司交易了 95,600 股股票，較其平均交易量 88,419 股有所增加。Clene 的 52 周低點為$2.28，52 周高點為$13.50。該股票的 50 日移動平均為$8.10，200 日移動平均為$5.29。公司的市值為$78.24 百萬，市盈率為-2.07，貝塔值為 0.72。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入與流出</h2>
</div><p>An institutional investor recently bought a new position in Clene stock. Jane Street Group LLC acquired a new stake in Clene Inc. (NASDAQ:CLNN - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,095 shares of the company's stock, valued at approximately $47,000. Jane Street Group LLC owned approximately 0.15% of Clene at the end of the most recent reporting period. Institutional investors own 23.28% of the company's stock.</p>
<div class="lb-trans"><p>一家機構投資者最近在 Clene 股票上建立了新頭寸。根據該公司在最近向證券交易委員會（SEC）提交的 13F 文件，Jane Street Group LLC 在第二季度收購了 Clene Inc.（納斯達克代碼：CLNN - 免費報告）的新股份。該機構投資者收購了 12,095 股公司股票，價值約$47,000。Jane Street Group LLC 在最近的報告期末持有 Clene 約 0.15% 的股份。機構投資者持有該公司 23.28% 的股份。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><p>Several equities analysts have commented on the stock. Wall Street Zen lowered shares of Clene from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a report on Saturday, August 16th. Canaccord Genuity Group cut their target price on shares of Clene from $83.00 to $48.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, August 18th. D. Boral Capital reiterated a &#34;buy&#34; rating and set a $23.00 price objective on shares of Clene in a research report on Thursday, September 25th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Clene in a research report on Tuesday, October 14th. Finally, Benchmark dropped their price objective on Clene from $33.00 to $31.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday, September 10th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $32.60.</p>
<div class="lb-trans"><p>幾位股票分析師對該股票發表了評論。華爾街 Zen 在 8 月 16 日的報告中將 Clene 的評級從 “持有” 下調至 “強烈賣出”。Canaccord Genuity Group 在 8 月 18 日的研究報告中將 Clene 的目標價從$83.00 下調至$48.00，並對該股票給予 “買入” 評級。D. Boral Capital 在 9 月 25 日的研究報告中重申了 “買入” 評級，並將 Clene 的目標價設定為$23.00。Weiss Ratings 在 10 月 14 日的研究報告中重申了對 Clene 的 “賣出（d-）” 評級。最後，Benchmark 在 9 月 10 日的研究報告中將 Clene 的目標價從$33.00 下調至$31.00，並對該股票給予 “買入” 評級。五位研究分析師對該股票給予 “買入” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，平均目標價為$32.60。</p>
</div><p><strong>View Our Latest Stock Report on Clene</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 Clene 股票報告</strong></p>
</div><h2>Clene Company Profile</h2>
<div class="lb-trans"><h2>Clene 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.</p>
<div class="lb-trans"><p>Clene Inc 是一家臨牀階段的製藥公司，專注於新型清潔表面納米技術（CSN）治療藥物的發現、開發和商業化。其主要藥物候選者是 CNM-Au8，目前正在進行多項臨牀試驗，包括一項已完成的第二階段平台試驗，以評估 CNM-Au8 在肌萎縮側索硬化症（ALS）患者中的安全性和有效性；已完成的第二階段概念驗證臨牀試驗，針對早期症狀性 ALS 患者；已完成的兩項開放標籤研究者盲法第二階段臨牀試驗，研究大腦能量代謝物；已完成的第二階段臨牀試驗，治療慢性視神經病變中的視覺通路缺陷，以實現穩定復發型多發性硬化症的再髓鞘化；以及針對帕金森病患者的第二階段臨牀試驗。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Clene</li>
<li>Election Stocks: How Elections Affect the Stock Market</li>
<li>AMD to $300 Looks Easy—Here’s Why $500 Could Be Next</li>
<li>How to Buy Cheap Stocks Step by Step</li>
<li>$5B+ in Buybacks: What DraftKings, AppLovin, and Altria Are Telling You</li>
<li>Insider Buying Explained: What Investors Need to Know</li>
<li>4 High-Yield Real Estate Stocks to Buy as Investors Get Defensive</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票</li>
<li>選舉股票：選舉如何影響股市</li>
<li>AMD 到$300 看起來很容易——這是為什麼$500 可能是下一個</li>
<li>如何逐步購買便宜股票</li>
<li>超過$5B 的回購：DraftKings、AppLovin 和 Altria 在告訴你什麼</li>
<li>內部購買解釋：投資者需要知道什麼</li>
<li>4 只高收益房地產股票，適合投資者採取防禦性策略</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xOTg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CLNN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Clene Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Clene 嗎？</h2>
</div><p>Before you consider Clene, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Clene 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clene wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Clene 並不在名單上。</p>
</div><p>While Clene currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Clene 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Clene（納斯達克代碼：CLNN）公佈季度財報，每股收益比預期低 0.25 美元